The global ambulatory surgical equipment market is valued at USD 7.39 billion in 2026 and is expected to reach USD 14.58 billion by 2035, growing at a 7.85% CAGR. North America dominates with 34% market share, while Asia Pacific is the fastest-growing region. Endoscopy and laparoscopy systems lead by product type at 18% share, with compact intraoperative imaging expected to grow fastest. Independent ambulatory surgical centers account for 42% of the market.

Royal Philips announced FDA 510(k) clearance for its Verida spectral CT system, an AI-powered imaging device that combines always-on spectral imaging with deep learning reconstruction. The system processes 145 images per second, enabling exam completion in under 30 seconds—twice as fast as previous versions—and can support up to 270 exams daily. Verida is indicated for diagnostic imaging across radiology, cardiology, oncology, and lung cancer screening applications.

The IoT in healthcare market is projected to grow from USD 207.4 billion in 2026 to USD 483.72 billion by 2031, with a CAGR of 18.46%. Growth is driven by remote patient monitoring adoption, connected medical devices, digital health advancements, and declining sensor costs. North America leads the market while Asia-Pacific emerges as the fastest-growing region.

Royal Philips announced that Dr. Carla Goulart Peron, Chief Medical Officer, has been appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC). MDIC is a public-private partnership that collaborates with the FDA to accelerate patient access to medical device innovations. Dr. Peron will contribute her expertise in bridging clinical evidence and innovation to strengthen MDIC's work in regulatory science and quality standards.

Royal Philips announced the launch of IntraSight Plus, an intuitive interventional guidance platform for minimally invasive coronary procedures that has received FDA 510(k) clearance and CE marking. The integrated system combines diagnostic and treatment planning tools, enabling up to 47% system operation time savings and streamlined workflow efficiency in catheterization labs across the USA and Europe.

Royal Philips announced the expansion of its digital pathology portfolio with a new cloud-enabled Philips IntelliSite Pathology Solution powered by AWS. The fully cloud-based platform helps healthcare organizations scale digital pathology workflows, improve productivity, and manage large volumes of high-resolution pathology images without on-premise infrastructure complexity. The solution supports secure remote access, data management, and AI-enabled diagnostics across health systems.

The global Respiratory Disease Testing Market is projected to grow from USD 5.99 billion in 2025 to USD 9.32 billion by 2032, with a CAGR of 6.50%. Growth is driven by advances in molecular diagnostics, digital imaging, telemedicine, and strategic partnerships. However, 2025 tariff revisions have impacted supply chains, prompting organizations to adopt flexible sourcing strategies and invest in local production capabilities.

Royal Philips-coordinated SHERPA research consortium has launched seven clinical studies across five European medical centers to validate AI and robotics-assisted workflows for minimally invasive brain aneurysm and liver tumor treatments. The four-year project, funded with EUR 21.5 million through the EU Innovative Health Initiative and industry partners, aims to address physician shortages by automating repetitive tasks and supporting decision-making in complex interventional procedures.

The global anti-snoring devices market is expected to grow from $1.81 billion in 2025 to $3.36 billion by 2033, with an 8.04% CAGR. Growth drivers include rising obesity rates, increased awareness of health risks associated with snoring, technological innovations, and improved e-commerce accessibility. Major players like Philips, ResMed, and SomnoMed are leading the market with advanced solutions.

The global digital twins in healthcare market is projected to grow from USD 2.22 billion in 2025 to USD 69.67 billion by 2035, with a CAGR of 41.17%. Growth is driven by AI-powered virtual modeling, precision medicine initiatives, and real-time patient data integration. The U.S. market alone is expected to reach USD 27.34 billion by 2035. Key applications include personalized medicine, drug discovery, and clinical research, with hospitals and clinics being the largest end-use segment.

The article highlights Taiwan Semiconductor Manufacturing (TSM) as a critical but overlooked player in the global AI revolution. Founded in 1987 by Morris Chang, TSM pioneered the foundry-based semiconductor business model, allowing design companies to specialize while TSM handled manufacturing. The company has become essential to major tech firms and benefits from long-term trends like digital transformation, cloud computing, and artificial intelligence.

The global tele-monitoring services market is valued at USD 36.59 billion in 2026 and is expected to reach USD 164.55 billion by 2035, growing at an 18.18% CAGR. North America leads the market while Asia Pacific shows the fastest growth. Remote patient monitoring dominates by service type, with wearables and mobile devices driving device segment growth. Key drivers include rising chronic disease prevalence, aging populations, and technological advancements in IoT and AI.